Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Clin Lipidol. 2010 Sep-Oct;4(5):365-70. doi: 10.1016/j.jacl.2010.08.008. Epub 2010 Aug 19.

Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression.

Author information

  • 1Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, 6565 Fannin, M.S. A-601, Houston, TX 77030, USA.

Abstract

BACKGROUND:

Although low-density lipoprotein cholesterol (LDL-C) traditionally has been the focus of treatment guidelines and clinical trials of lipid therapy, patients continue to have cardiovascular disease (CVD) events despite effective lowering of their LDL-C levels, suggesting the influence of other risk factors. High-density lipoprotein cholesterol (HDL-C) levels have been shown to be inversely associated with CVD risk in epidemiological studies.

METHODS:

Meta-analyses and clinical trials that reported on the potential relation between HDL-C and CVD were reviewed.

RESULTS:

Low HDL-C level is associated with increased CVD risk. Statins reduce CVD events in patients with low HDL-C, and fibrates benefit patients with low HDL-C and high triglyceride levels. The benefit of statins on event reduction may be related to their effects on HDL-C. However, not all therapies that increase HDL-C reduce CVD events. Imaging trials have provided evidence of the combined influence of HDL-C and LDL-C on surrogate end points.

CONCLUSION:

Drugs in the same class may have different effects on HDL-C, and these different lipid effects may translate into different effects on atherosclerosis and CVD events. A new class of agents, cholesteryl ester transfer protein inhibitors, is being examined in ongoing trials to determine whether dalcetrapib may have different effects than torcetrapib, which increased levels of HDL-C but was associated with increased adverse events. In addition, ongoing trials are examining whether targeting both HDL-C and LDL-C, by combining a second agent such as niacin with a statin, leads to greater benefit on CVD and clinical events.

Copyright © 2010 National Lipid Association. Published by Elsevier Inc. All rights reserved.

PMID:
21122680
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk